Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19-nortestosterone.

Abstract

Ten patients (8 female, 2 male) with systemic lupus erythematosus (SLE) were entered into an open trial with the anabolic steroid 19-nortestosterone (19-nor). Their clinical condition did not improve, nor were significant changes observed in the majority of laboratory data. However, overall the platelet count rose, and in patients with abnormal levels of T lymphocytes bearing receptors for IgG Fc treatment returned the values to normal. Despite this latter result, suppressor cell activity remained slightly below the normal range throughout the study period.

• Authors: R A Hazelton, A B McCruden, R D Sturrock, W H Stimson
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 42 Issue 2 Pg. 155-7 (Apr 1983) ISSN: 0003-4967 [Print] England
• PMID: 6342550 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Receptors, Fc
• Nandrolone

Topics

• Clinical Trials as Topic
• Female
• Humans
• Lupus Erythematosus, Systemic (drug therapy, immunology)
• Male
• Middle Aged
• Nandrolone (therapeutic use)
• Platelet Count
• Receptors, Fc (immunology)
• T-Lymphocytes (drug effects, immunology)